Marketing compounded GLP-1 products without writing your own warning letter

Compounded semaglutide and tirzepatide are the most heavily scrutinised marketing category in telehealth, and the scrutiny is documented. We maintain an index of every FDA warning letter issued to telehealth and compounding companies over compounded GLP-1 marketing, built row by row from the letters themselves rather than from summaries. The current count, the enforcement rounds and the tally for each violation are all on that page.

What is striking is not the volume. It is the uniformity. Misbranding is cited throughout the series, and behind it come the claim that a compounded drug is FDA-approved, the comparison to the brand-name product, and the promise of safety or effectiveness.

These are not exotic failures. They are four sentences that a copywriter writes without thinking, and they are the same sentences that stall a certification review.

The four sentences

"FDA-approved semaglutide." The compounded preparation is not an approved product. Approval attaches to a specific product from a specific manufacturer, and a compounded preparation containing the same active ingredient does not inherit it. Neither does "made with FDA-approved ingredients", which is a sentence engineered to be read as the claim it disclaims.

"The same as the brand-name drug, for less." Comparison is where the largest number of these letters land after the approval claim. A compounded preparation has not been shown to be equivalent to the approved product in safety, effectiveness or quality, because nobody has reviewed it for that. Comparative pricing framed against a named brand carries the equivalence implication even where the text does not state it.

"Lose up to X pounds." An effectiveness claim about a product that has not been reviewed for effectiveness. Borrowing trial results from the approved drug and presenting them for a compounded preparation is the most common version, and it is the version that is hardest to argue was accidental.

"Safe and effective." Both halves are regulatory terms of art here, and both describe a review that has not happened for a compounded product.

What you can say

This is the part that gets lost in compliance advice that is all prohibition. Plenty is sayable, and it converts.

You can describe what the preparation is, including its active ingredient. You can be clear that it is compounded and prepared by a named pharmacy under a prescription for the individual patient. You can describe your clinical model honestly: who prescribes, what the consultation involves, what follow-up looks like, how dosing is supervised.

You can talk about service. Speed of consultation, quality of clinical support, what happens if the patient has a question at eleven at night, how cancellation works. In a category where the product is broadly similar between competitors, service is the honest differentiator and it is entirely unrestricted.

And you can be plain about what the product is not. Brands consistently underestimate how well that converts with the specific customer who is hesitating because they suspect they are being sold something dressed up.

The word "personalised" deserves its own paragraph

Personalised dosing is a claim, and the warning letter dataset includes it as a category of its own. Where a compounded preparation is presented as tailored to the individual, the presentation has to match what is actually happening clinically. If the personalisation is a prescriber choosing between three standard strengths, describing it as a bespoke formulation is a claim about the product rather than about the service.

The same caution applies to added ingredients presented as enhancements. Framing an additive as improving outcomes is an effectiveness claim about a preparation nobody has studied.

Where the claims actually live

The audit that matters covers more than the product page. In practice the offending sentence turns up in:

• Paid ad copy and the headline of the landing page it points at.
• The quiz result screen, which is where "your personalised plan" tends to live.
• Email sequences, particularly the abandoned-cart and win-back flows written eighteen months ago by somebody who has left.
• Affiliate and influencer content driving into your funnel.
• Customer support macros, which is where a support agent reassures a nervous customer with a comparison to the brand-name drug in writing.

The last two are the ones brands forget, and both are discoverable.

Doing this once, properly

Write a claims allowlist. One page per product: what the preparation is, what the pharmacy relationship is, what may be said, what may not be said, and the exact approved phrasing for the two or three things everybody wants to say. Get it signed off by whoever owns clinical. Give it to every copywriter, agency and affiliate you work with.

Then sweep everything that is already live against it, including the channels above.

That sweep is the largest single piece of preparation for a certification application in this category, and it is the reason applications in weight management take longer than their operators expect. It is also work that pays for itself independently of certification, because what disqualifies an application and what draws a warning letter are, in this category, very nearly the same list.

Rewriting the four sentences

The useful exercise is not deleting the claim, it is finding what the claim was doing and meeting that need honestly.

The approval claim was doing reassurance. The patient wants to know this is not something dubious. Reassure them with the things that are true: a named prescriber, a named pharmacy, a real clinical review, a route back to a clinician.

The comparison was doing price justification. Compare against your own plans instead. Explain what is included, what the consultation covers, what happens if a prescriber declines. Comparison against your own offer is unrestricted and it converts better than an implication the reader half suspects.

The outcome claim was doing motivation. Motivation can come from the process rather than the product: what the first month looks like, how dosing is supervised, what support exists when something is difficult.

The safety claim was doing objection handling. Handle the objection directly. Say what the preparation is, say what review it has and has not had, and say who is accountable. Prospects in this category are more sceptical than the copy usually assumes, and candour outperforms reassurance that sounds rehearsed.

Keeping it fixed

Re-audit when the product changes, when the pharmacy relationship changes, and when the supply position of the approved product changes, because copy written against one set of circumstances quietly becomes wrong when they move. Put a date on the allowlist and a calendar reminder against it. That is the whole maintenance burden, and it is smaller than one round of correspondence with a reviewer.